menu search

Coherus announces toripalimab data at 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics

— Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1 ...

October 14, 2023, 4:30 pm

Gritstone bio: renewed excitement for its covid-19 vaccine

GRTS's COVID-19 vaccine may produce more durable immunity than current mRNA vaccines, according to data from phase 1 ...

October 14, 2023, 2:21 am

Artivion's ongoing clinical studies could drive significant growth starting in 2025

Artivion has used M&A to reposition itself towards growth opportunities in aortic disease care and heart valves. The company's legacy operations contr...

October 13, 2023, 2:37 pm

Phio jumps 91% on encouraging preclinical cancer drug data

Data from preclinical studies show that Phio's (PHIO) cancer drug PH-894 is effective in BRD4 inhibitio...

October 12, 2023, 12:47 pm

Davita says news of ozempic's potential in treating kidney disease may have only limited impact for patients, says further studies will be needed

Dialysis company DaVita Inc. DVA, -16.86% issued a statement on Thursday in response to the news Wednesday from Novo Nordisk that its Ozempic treatmen...

October 12, 2023, 8:43 am

Jaguar health to present october 17 at the lytham partners fall 2023 investor conference and october 18 at the bio investor forum

Top line results expected in the coming weeks for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related ...

October 12, 2023, 8:30 am

I've sold my granite point mortgage trust position and won't re-enter

Granite Point Mortgage Trust is a small mortgage REIT with a high risk of a dividend cut. studies show ...

October 11, 2023, 10:57 pm

Eli lilly: the glp-1 opportunity, while increasingly recognized, is vastly underestimated

Eli Lilly is expected to receive FDA approval for tirzepatide, an obesity medication, and has two other medications in phase 3 clinical ...

October 11, 2023, 5:33 pm

Presentations at idweek 2023 highlight potentially differentiated immunogenicity of gritstone bio’s next generation covid-19 vaccine

— High neutralizing antibody (nAb) responses sustained through at least 12 months, highlighting potential for durable clinical protection — — T ...

October 11, 2023, 11:10 am

Electric metals closes final tranche of quail bend financing; raises c$5m in total

Electric Metals (TSX-V:EML) (USA) Limited said it has closed the second and final tranche of its previously announced non-brokered financing with Quai...

October 10, 2023, 2:59 pm

Down 45%, is intellia a buy?

Intellia has declined over the past year even as its candidates for severe diseases have advanced in clinical ...

October 10, 2023, 2:00 pm

Roche's (rhhby) vabysmo positive in late-stage rvo studies

Roche (RHHBY) Vabysmo maintains vision improvements with extended treatment intervals of up to four months in phase III ...

October 10, 2023, 1:32 pm

Beam focuses on developing gene drug for growth

While BEAM's pipeline candidates are in early-stage clinical studies, their development is progressing ...

October 10, 2023, 11:16 am

Wti oil: on track for biggest weekly loss in months but oversold studies may slow bears

WTI oil remains at the back foot and holding at the lowest in five weeks on Friday, following a strong fall in past two days (down 7.6%). Renewed conc...

October 6, 2023, 11:13 am

Gritstone bio announces presentations from phase 1 studies evaluating next-generation vaccine candidate for covid-19 at idweek 2023

EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop t...

October 4, 2023, 8:05 pm

Structure therapeutics: tipping the scales in obesity management

Structure Therapeutics' oral small molecule GLP-1, GSBR-1290, has shown promising results in Phase 1b studies<...

October 3, 2023, 11:28 pm

Tg therapeutics: racing against time while their differentiators are still relevant

TG Therapeutics has transitioned from a developer of oncology drugs to a commercial-stage neurology company with the approval of its multiple sclerosi...

October 3, 2023, 2:26 pm

Aligos therapeutics announces award of an $8.5 million niaid contract to advance development of best-in-class pan-coronavirus protease inhibitor, alg-097558

– NIAID contract will support conducting nonclinical and clinical studies to advance ALG-097558 into ...

October 3, 2023, 11:30 am


Search within

Pages Search Results: